Nicole Erin Kinsey White

Array ( [id] => 12306426 [patent_doc_number] => 09938508 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-10 [patent_title] => Polypeptides specific to [patent_app_type] => utility [patent_app_number] => 15/437820 [patent_app_country] => US [patent_app_date] => 2017-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 10 [patent_no_of_words] => 60345 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15437820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12091313 [patent_doc_number] => 20170348405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES' [patent_app_type] => utility [patent_app_number] => 15/419523 [patent_app_country] => US [patent_app_date] => 2017-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 102 [patent_figures_cnt] => 102 [patent_no_of_words] => 21774 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15419523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12166142 [patent_doc_number] => 09884905 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Bispecific HIV-1 neutralizing antibodies' [patent_app_type] => utility [patent_app_number] => 15/414822 [patent_app_country] => US [patent_app_date] => 2017-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 13190 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11956087 [patent_doc_number] => 20170260239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'MODIFIED VP1-CAPSID PROTEIN OF PARVOVIRUS B19' [patent_app_type] => utility [patent_app_number] => 15/408485 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8496 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15408485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12177464 [patent_doc_number] => 20180036399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'Molecular Antigen Array' [patent_app_type] => utility [patent_app_number] => 15/407920 [patent_app_country] => US [patent_app_date] => 2017-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 86381 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15407920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16563266 [patent_doc_number] => 10888613 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-12 [patent_title] => Method of producing cells resistant to HIV infection [patent_app_type] => utility [patent_app_number] => 16/076655 [patent_app_country] => US [patent_app_date] => 2017-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 24 [patent_no_of_words] => 34429 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960605 [patent_doc_number] => 20200164054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => INTRA-LESIONAL CMV-BASED CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 16/064906 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16064906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14088083 [patent_doc_number] => 10239935 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-26 [patent_title] => Human immunodeficiency virus neutralizing antibodies [patent_app_type] => utility [patent_app_number] => 15/379157 [patent_app_country] => US [patent_app_date] => 2016-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 40 [patent_no_of_words] => 46201 [patent_no_of_claims] => 71 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15379157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16703170 [patent_doc_number] => 10953083 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts [patent_app_type] => utility [patent_app_number] => 16/061316 [patent_app_country] => US [patent_app_date] => 2016-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 16897 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649622 [patent_doc_number] => 20170145523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'METHODS FOR DETERMINING RESISTANCE OR SUSCEPTIBILITY TO HIV ENTRY INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/362141 [patent_app_country] => US [patent_app_date] => 2016-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 25192 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15362141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17604045 [patent_doc_number] => 11332516 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => Antibody purification method [patent_app_type] => utility [patent_app_number] => 15/779391 [patent_app_country] => US [patent_app_date] => 2016-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 6 [patent_no_of_words] => 6834 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15779391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618377 [patent_doc_number] => 20170128564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL' [patent_app_type] => utility [patent_app_number] => 15/360175 [patent_app_country] => US [patent_app_date] => 2016-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 21348 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15360175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16369298 [patent_doc_number] => 10801041 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => T7 alpha viral vector system [patent_app_type] => utility [patent_app_number] => 15/776855 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11637 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13563793 [patent_doc_number] => 20180333444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => BACTERIOPHAGE COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/777615 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35087 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13729663 [patent_doc_number] => 20180369299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => NOVEL VIBRIO PARAHAEMOLYTICUS BACTERIOPHAGE VIB-PAP-1 AND USE THEREOF FOR INHIBITING PROLIFERATION OF VIBRIO PARAHAEMOLYTICUS [patent_app_type] => utility [patent_app_number] => 16/064698 [patent_app_country] => US [patent_app_date] => 2016-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16064698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14324103 [patent_doc_number] => 10293044 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Particulate formulations for improving feed conversion rate in a subject [patent_app_type] => utility [patent_app_number] => 15/332308 [patent_app_country] => US [patent_app_date] => 2016-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 23 [patent_no_of_words] => 20659 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15332308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12505395 [patent_doc_number] => 09999237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-19 [patent_title] => Method of inhibiting the growth of [patent_app_type] => utility [patent_app_number] => 15/297587 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 7461 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15297587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13533645 [patent_doc_number] => 20180318365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 15/769057 [patent_app_country] => US [patent_app_date] => 2016-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11422765 [patent_doc_number] => 20170030910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'FELINE LEUKEMIA VIRUS TRANS-MEMBRANE PROTEIN P15E FOR DIAGNOSIS OF FELV INFECTION' [patent_app_type] => utility [patent_app_number] => 15/294712 [patent_app_country] => US [patent_app_date] => 2016-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6089 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15294712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13537303 [patent_doc_number] => 20180320198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => METHODS AND COMPOSITIONS FOR INTEGRATION-DEFECTIVE LENTIVIRAL VECTORS [patent_app_type] => utility [patent_app_number] => 15/768438 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768438 [rel_patent_id] =>[rel_patent_doc_number] =>)